Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis

Pediatric Research

Volumn 59, Issue 2, 2006, Pages 281-286

  Rosso, Diego A ^c,d,e   Karis, Jenny ^a,b   Braier, Jorge L ^c   Henter, Jan Inge ^b   Fadeel, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^d HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2 RECEPTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; CELL RECEPTOR; GLYCOPROTEIN; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; FEMALE; GRANULOMATOUS INFLAMMATION; HEMATOPOIETIC SYSTEM; HISTIOCYTOSIS X; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LANGERHANS CELL; LIVER; LUNG; MALE; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SPLEEN; BLOOD; CHILD; COHORT ANALYSIS; INFANT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GLYCOPROTEINS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; MALE; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 33646715367     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.pdr.0000196375.47889.5b     Document Type: Article

References (40)

1. Arceci RJ 1999 The histiocytoses: the fall of the Tower of Babel. Eur J Cancer 35:747-767
2. Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, Komp D, Michaelis J, Nicholson S, Potschger U, Pritchard J, Ladisch S, Histiocyte Society 2001 A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 138:728-734.
3. Geissmann F, Lepelletier Y, Fraitag S, Valladeau J, Bodemer C, Debre M, Leborgne M, Saeland S, Brousse N 2001 Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 97:1241-1248
4. Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM Langerhans-cell histiocytosis "insight into DC biology." Trends Immunol 2003;24:190-196
5. Fadeel B, Henter JI 2003 Langerhans-cell histiocytosis: neoplasia or unbridled inflammation? Trends Immunol 24:409-410
6. Egeler RM, Favara BE, van Meurs, M, Laman JD, Claassen E 1999 Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 94:4195-4201
7. Egeler RM, Favara BE, Laman JD, Claassen E 2000 Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions. Eur J Cancer 36:2105-2110
8. Andersson By U, Tani E, Andersson U, Henter JJ 2004 Tumor necrosis factor, interleukin 11 and leukemia inhibitory factor produced by Langerhans cells in Langerhans cell histiocytosis. J Pediatr Hematol Oncol 26:706-711
9. Braier J, Chantada G, Rosso D, Bernaldez P, Amaral D, Latella A, Balancini B, Masautis A, Goldberg J 1999 Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol 16:377-385
10. Bernstrand C, Cederlund K, Sandstedt B, Ahstrom L, Lundell M, Dahlquist G, Henter JI 2001 Pulmonary abnormalities at long-term follow-up of patients with Langerhans cell histiocytosis. Med Pediatr Oncol 36:459-468
11. Rosso DA, Ripoli MF, Roy A, Diez RA, Zelazko ME, Braier JL 2003 Serum levels of interleukin-1 receptor antagonist and tumor necrosis factor-α are elevated in children with Langerhans cell histiocytosis. J Pediatr Hematol Oncol 25:480-483
12. Henter JI, Karlen J, Calming U, Bernstrand C, Andersson U, Fadeel B 2001 Successful treatment of Langerhans'-cell histiocytosis with etanercept. N Engl J Med 345:1577-1578
13. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
14. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR 1998 Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367
15. Hayakawa Y, Screpanti V, Yagita H, Grandien A, Ljunggren HG, Smyth MJ, Chambers BJ 2004 NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 172:123-129
16. Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, Pascual V, Hood LE, Clark EA 1998 OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161:6113-6121
17. Vidal K, van den Broek P, Lorget F, Donnet-Hughes A 2004 Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. Pediatr Res 55:1001-1008
18. Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, Ewings ME, Mohaupt M, Herring SW, Clark EA 2001 Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 166:1482-1491
19. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, Nielsen JL, Hjorth-Hansen H, Waage A, Sundan A, Borset M Nordic Myeloma Study Group 2001 Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98:2269-2271.
20. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek, EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp, B, Vanderkerken K 2001 Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534-3540
21. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W 2002 High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment. Arthritis Rheum 46:1744-1753
22. Rosso DA, Roy A, Zelazko M, Braier JL 2002 Prognostic value of soluble interleukin 2 receptor levels in Langerhans cell histiocytosis. Br J Haematol 117:54-58
23. da Costa, CE, Annels NE, Faaij CM, Forsyth RG, Hogendoom PC, Egeler RM 2005 Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med 201:687-693
24. Rolland A, Guyon L, Gill M, Cai YH, Banchereau J, McClain K, Palucka AK 2005 Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol 174:3067-3071
25. Farran RP, Zaretski E, Egeler RM 2001 Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol 23:54-56
26. Arzoo K, Sadeghi S, Pullarkat V 2001 Pamidronate for bone pain from osteolytic lesions in Langerhans' cell histiocytosis. N Engl J Med 345:225-
27. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC 2002 Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680-686
28. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A 2002 Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100:3002-3007
29. Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H 2005 The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 54:479-487
30. Bernstein CN, Sargent M, Leslie WD 2005 Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm Bowel Dis 11:325-330
31. Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippitt JM, Child JA, Dunstan C, Felsburg PJ, Morgan GJ, Carding SR 2003 Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19:849-861
32. Cremer I, Dieu-Nosjean MC, Marechal S, Dezutter-Dambuyant C, Goddard S, Adams D, Winter N, Menetrier-Caux C, Sautes-Fridman C, Fridman WH, Mueller CG 2002 Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood 100:3646-3655
33. Rivoilier A, Mazzorana M, Tebib J, Piperno M, Aitsiselmi T, Rabourdin-Combe C, Jurdic P, Servet-Delprat C 2004 Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104:4029-4037
34. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P 2001 Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol 145:685-690
35. Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M, Delvenne P, Louis E 2004 Increased expression of receptor activator of NF-κB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 138:491-498
36. Calming U, Henter JI 1998 Elevated erythrocyte sedimentation rate and thrombocytosis as possible indicators of active disease in Langerhans' cell histiocytosis. Acta Paediatr 87:1085-1087
37. Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A 2004 Serum osteoprotegerin but not receptor activator of NF-κB ligand correlates with Larsen score in rheumatoid arthritis. Ann Rheum Dis 63:216-217
38. Kannourakis G, Abbas A 1994 The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer 23:S37-S40
39. Kubota A, Hasegawa K, Suguro T, Koshihara Y 2004 Tumor necrosis factor-α promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. J Rheumatol 31:426-435
40. Kong YY, Boyle WJ, Penninger JM 2000 Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 21:495-502